WeChatshare
The 5th International Cell & Gene Therapy China Summit & Exhibition

You can share it to WeChat via the Qr code.

Eventsshare
The 5th International Cell & Gene Therapy China Summit & Exhibition

Enter the applet sharing event using WeChat scan.

Event Background


With over 20,000 global CGT Drugs now in development 2 local Chinese drugs have gone to the market. The International Cell & Gene Therapy China Summit(CGCS) returned for its 5th year as the industry’s largest networking opportunity to date in the Asia area, showcasing exclusive new data from the movers and shakers in the field. 

 

In CGCS2023, 2500+ attendees heard insights from 80+ world-class speakers from large pharma, innovative biotech, and academia, across 3 days of content and 6 main topics( discovery, clinical development, CMC, bioprocessing, QA/QC,  and logistics). Exhibitors from Biotech/ Biopharma, CDMO, CRO, Solution Providers, Reagents and Consumables, Academia, and Research Institutes.


CGCS2024 Agenda_The 5th Cell & Gene Therapy China Summit 2024, May 22-24, 2024, Nanjing, China_01.png

Agenda

CGCS2024 Agenda_The 5th Cell & Gene Therapy China Summit 2024, May 22-24, 2024, Nanjing, China_03.png



Our Speakers
  • Director, Center for Biologics Evaluation and Research, FDAPeter Marks, MD, PhD
    Peter Marks, MD, PhD
    Director, Center for Biologics Evaluation and Research, FDA
    Dr. Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University. Following this, he completed an Internal Medicine residency and Hematology/Medical Oncology fellowship at Brigham and Women’s Hospital in Boston, where he subsequently joined the attending staff as a clinician-scientist and eventually served as Clinical Director of Hematology.
  • Review Director, Office of Cellular and Tissue-based Products, PMDAYoshiaki Maruyama Ph.D.
    Yoshiaki Maruyama Ph.D.
    Review Director, Office of Cellular and Tissue-based Products, PMDA
    I am currently a Review Director at the Office of Cellular and Tissue-based Products at the Pharmaceuticals and Medical Devices Agency (PMDA), Japan. In 2008, I joined PMDA as an officer in the Office of Compliance and Standards where I was also a secretariat for the Japanese Pharmacopoeia till 2012. I participated as Ministry of Health, Labour and Welfare (MHLW) and the PMDA topic leader for the development of ICH guidelines and Annexes on ?Evaluation and Recommendation of Pharmacopoeial Texts for use in the ICH Regions (Q4B)?. Prior to joining PMDA, I was a research fellow at the University of Calgary, Canada from 2001 till 2005 and National Center of Neurology and Psychiatry (NCNP) Tokyo, Japan from 2005 till 2008.
  • ChairmanAkihiro Shimosaka
    Akihiro Shimosaka
    ACTO Chairman
  • CSO/ Founder of Legend Biotech & Wondercell BiopharmaceuticalsFrank Fan
    Frank Fan
    CSO/ Founder of Legend Biotech & Wondercell Biopharmaceuticals
  • Co-founder, Chairman of the Board, CEO, CSO at CARsgen TherapeuticsZonghai Li
    Zonghai Li
    Co-founder, Chairman of the Board, CEO, CSO at CARsgen Therapeutics
  • Founder, Chairman and CEO, Neukio BiotherapeuticsRICHARD LIQUN WANG
    RICHARD LIQUN WANG
    Founder, Chairman and CEO, Neukio Biotherapeutics
    -VP & CTO, Fosun Pharma -Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first -CAR-T product) in less than three years -COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies -Head of Operations, GSK R&D Center in China -Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China -Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA -Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA
  • VPJie Zhang
    Jie Zhang
    Novartis VP
  • CEO,  IASO BioTherapeuticsMaxwell Wang
    Maxwell Wang
    CEO, IASO BioTherapeutics
    汪文博士在安徽医科大学获得临床医学学士学位(B.M.),曾在上海市中西医结合医院任骨科住院医师、主治医师。随后在同济大学获得人体解剖学硕士学位(M.M.)、同济大学/德国Universität Würzburg外科学博士学位(M.D.)、英国University of Aberdeen分子生物学博士学位(Ph.D)。后在美国University of Connecticut Health Center担任博士后研究员,在《Clin Cancer Res》、《Blood》等杂志发表细胞治疗相关SCI论文20余篇。 汪文博士于2013年加入工业界,曾在西比曼生物科技集团(Nasdaq: CBMG)、药明巨诺生物科技有限公司(HKEX:02126)、先声药业集团(SEHK:02096)担任医学总监、临床开发高级总监、临床科学执行总监。自2006年起从事细胞治疗工作十余年,作为项目主要成员成功申报中国第一个靶向CD19的CAR-T临床试验。汪文博士于2020年3月担任驯鹿生物首席医学官,带领临床开发团队快速推进CT103A临床试验项目。2021年4月,汪文博士正式担任公司首席执行官,全面主持公司经营管理工作。
  • Founder/Chairman/Chief Scientific Officer of PersonGen BioTherapeuticsLin Yang
    Lin Yang
    PersonGen BioTherapeutics Founder/Chairman/Chief Scientific Officer of PersonGen BioTherapeutics
  • SVP R&DHequn Yin
    Hequn Yin
    Iovance SVP R&D
  • Former FDA Reviewer, Founder of Evergreen TherapeuticsXin Du
    Xin Du
    Former FDA Reviewer, Founder of Evergreen Therapeutics
    杜新博士曾在美国FDA任CMC审评官,负责生物药IND和BLA的审评工作。随后在AVENTIS-PASTUER/SANOFI,WYETH/PFIZER,NOVARTIS,BMS等跨国药企工作。在20 多年医药工业的工作中, 杜新博士获得4个生物药品许可证的FDA批准, 2个生物药品在欧盟和加拿大的批准,以及无数IND在美国、中国、欧盟、和其他国家的批准,涉及大小分子、细胞和基因、溶瘤病毒和药品器械组合等各种类型的产品。并具有在超过30个国家管理上市药品的经验。
  • Director of the Division of Biotherapy, 301 HospitalPro. Weidong HAN
    Pro. Weidong HAN
    Director of the Division of Biotherapy, 301 Hospital
    中国人民解放军总医院301医院生物治疗科主任,解放军总医院生命科学院分子免疫学研究室主任,博士研究生导师,总后勤部科技新星。主要从事干细胞与组织再生基础与临床研究,肿瘤治疗抵抗机制与临床研究。创建了解放军总医院首个生物治疗病区,担任首任主任。干细胞研究方面,证实了表皮干细胞的体外多潜能分化特征;在肿瘤细胞治疗研究方面走在前列,系统研究了Macro domain家族蛋白1在肿瘤治疗抵抗中的机制,识别了多个肿瘤抵抗相关非编码基因;建立了多项肿瘤靶向免疫细胞治疗体系,在国内率先在国际临床试验机构注册了多种CART治疗的临床试验,并在临床应用。
  • CEO, JuventasLulu LV
    Lulu LV
    CEO, Juventas
    2007年以前,吕博士于主要从事造血干细胞和间充质干细胞临床和科研工作。2007年加入跨国制药企业后,从事血液和肿瘤领域创新药物研发和新产品战略规划工作逾10年,曾在诺华、健赞、罗氏、阿斯利康和默沙东等跨国公司关键岗位任职,在靶向药物、免疫治疗和细胞治疗领域具有丰富的研发和产品生命周期管理经验。在格列卫、赫赛汀、泰瑞沙和可瑞达等划时代肿瘤产品的注册研发和市场拓展中发挥重要作用。
  • Founder, EnCureGenAimin Hui
    Aimin Hui
    Founder, EnCureGen
  • CSO, CanSinoBIOTao Zhu
    Tao Zhu
    CSO, CanSinoBIO
  • Chairman/CEO of CorreGeneXingwang Xie
    Xingwang Xie
    Chairman/CEO of CorreGene
  • Co-founder, President and China GM of HuidaGene TherapeuticsXuan Yao
    Xuan Yao
    Co-founder, President and China GM of HuidaGene Therapeutics
    在创立辉大基因之前,姚博士通过优化基因编辑技术,高效获得基因敲入小鼠模型并世界首次获得基因敲入猕猴;创新性使用CRISPR技术特异性敲除整条染色体,为包括唐氏综合症等疾病的治疗提供了新的途径;建立了高效的成体细胞基因敲入方法,为单基因遗传疾病治疗领域提供了技术方案。在新型基因编辑技术在动物模型的建立和疾病治疗中的应用领域拥有国际前沿的视野与商业转化的嗅觉。
  • Principal Investigator, The First Affiliated Hospital of Soochow UniversityZhengzheng Fu
    Zhengzheng Fu
    Principal Investigator, The First Affiliated Hospital of Soochow University
  • CSO, SineuGeneWei GUO
    Wei GUO
    CSO, SineuGene
  • CSO, VCANBIOYu Zhang
    Yu Zhang
    CSO, VCANBIO
  • CEO, Xueji BioFangfang Zhu
    Fangfang Zhu
    CEO, Xueji Bio
    上海海外高层次人才,上海交通大学长聘教轨副教授 兰州大学生物技术基地班毕业,北京大学细胞生物学博士,斯坦福大学医学院进行博士后研究
  • COO, NeurophthSU XIAO
    SU XIAO
    COO, Neurophth
  • Founder/ CEO/ CTO, Juncell TherapeuticsHuajun Jin
    Huajun Jin
    Founder/ CEO/ CTO, Juncell Therapeutics
  • CEO, Junjian BiotechChangyun XIONG
    Changyun XIONG
    CEO, Junjian Biotech
  • Co-founder&CTO, CirCodeYun Yang
    Yun Yang
    Co-founder&CTO, CirCode
    杨赟博士毕业于浙江大学获得生物信息学学位,并在浙江大学获得分子生物学和生物化学专业博士学位,后在美国北卡罗莱纳大学教堂山分校和加州大学洛杉矶分校完成博士后研究。曾任职中科院上海营养与健康研究所副研究员。长期从事RNA加工和翻译调控及其应用,尤其在RNA可变剪接和环形RNA翻译调控领域做了大量原创性工作。杨赟博士曾主持多项国家和上海市科研项目,获得中科院青年创新促进会会员、上海市科技启明星等荣誉。
  • CEO, StarryGeneYuan Cai
    Yuan Cai
    CEO, StarryGene
  • Director of the Biotherapy Center, Sun Yat-Sen University Cancer CenterJianchuan XIA
    Jianchuan XIA
    Sun Yat-Sen University Cancer Center Director of the Biotherapy Center, Sun Yat-Sen University Cancer Center
    Professor Xia Jianchuan graduated from Harbin Medical University in 1998 with a doctor of medicine; from 1998 to 2000, he was engaged in postdoctoral research in the Affiliated Tumor Hospital of Sun Yat-sen Medical University; from 2000 to 2003, he was engaged in tumor immunotherapy at Harvard University Dana-Farber Cancer Institute And tumor vaccine research. During this period, it was confirmed for the first time that the DC/tumor fusion cell vaccine can induce spontaneous breast cancer transgenic mice to produce an anti-tumor immune response, laying the foundation for the application of the DC/tumor fusion cell vaccine in the clinical treatment of tumors.
  • COOYujie Guo
    Yujie Guo
    UCELLO COO
  • CTOJames Wang
    James Wang
    Juventas CTO
  • CTOFeifei Qi
    Feifei Qi
    Imunopharm CTO
  • CSOUwe Marx
    Uwe Marx
    TissUse CSO
  • CEOGrace Zhou
    Grace Zhou
    ImmVira CEO
  • CEOLaura Hong
    Laura Hong
    GenView Bio CEO
  • CEOYann Chong Tan
    Yann Chong Tan
    Nuevocor CEO
  • ProfessorKangxin He
    Kangxin He
    The First Affiliated Hospital Professor
  • CEOJing Fan
    Jing Fan
    Hopstem CEO
  • CSOShane Gao
    Shane Gao
    ReuroRe Medical CSO
  • COOEmily TAN
    Emily TAN
    UniXell COO
  • VPBen Shaberman
    Ben Shaberman
    Foundation Fighting Blindness VP
  • CMOSam Barone
    Sam Barone
    Nanoscope CMO
  • CEOPaul Bresge
    Paul Bresge
    Ray Therapeutics CEO
  • CSOArun Upadhyay
    Arun Upadhyay
    Ocugen CSO
  • CMONadia Waheed
    Nadia Waheed
    Beacon Therapeutics CMO
  • ProfessorLejla Vajzovic
    Lejla Vajzovic
    Duke University Eye Center Professor
  • ProfessorDavid Boyer
    David Boyer
    USC School of Medicine Professor
  • ProfessorPeter Kaiser
    Peter Kaiser
    Cole Eye Institute Professor
  • DirectorSandy Qlintang
    Sandy Qlintang
    PT Kalbe Director
  • ProfessorBoon Seng SOH
    Boon Seng SOH
    A*STAR Professor
  • ProfessorThomas Hartung
    Thomas Hartung
    Johns Hopkins University Professor
  • CTOTadashi Umemoto
    Tadashi Umemoto
    Luxna Biotech CTO
  • CEOCarsten Rudolph
    Carsten Rudolph
    Ethris CEO
  • VPMengyang Zhong
    Mengyang Zhong
    Grit Bio VP
  • COOTina Wang
    Tina Wang
    Lion TCR COO
  • CEOPaul Song
    Paul Song
    NKGen Biotech CEO
  • Founder&CEOSeong-Wook Lee
    Seong-Wook Lee
    Rznomics Founder&CEO
  • ProfessorRyuichi Morishita
    Ryuichi Morishita
    Osaka University Professor
  • CEOBiao Zheng
    Biao Zheng
    BRL Medicine CEO
  • CSOCecilia Zhang
    Cecilia Zhang
    Biosyngen CSO
  • Head - Commercial and Market AccessRebu Ninan
    Rebu Ninan
    Immuneel Therapeutics Head - Commercial and Market Access
  • CEOShin Hatou
    Shin Hatou
    Cellusion CEO
  • CDOHoward Fang
    Howard Fang
    Alpha Biopharma CDO
  • CEOGreg Kunst
    Greg Kunst
    Aurion Biotech CEO
  • CEOEd Zhang
    Ed Zhang
    Overland Pharmaceuticals CEO
  • CSOShin-Il Kim
    Shin-Il Kim
    Therabest CSO
  • VP, HyaMabChaohui Dai
    Chaohui Dai
    VP, HyaMab
  • CSOHao Shen
    Hao Shen
    Fosun Kite CSO
  • Co-founder/ VP, CureMedChijian Zuo
    Chijian Zuo
    CureMed Co-founder/ VP, CureMed
    左炽健,博士,苏州科锐迈德生物医药科技有限公司联合创始人、副总经理。硕士毕业于上海交通大学医学院健康科学研究所,博士毕业于德国弗莱堡大学药学系。目前主要从事环状RNA平台建设,包括新的成环框架的研发,环状RNA功能元件的筛选及优化,以及环状RNA工艺/生产开发研究,为国内领先的环状RNA平台。同时将环状RNA与多种递送技术相结合,应用于肿瘤免疫药物、传染病疫苗、肿瘤疫苗、TCR-T/CAR-T细胞治疗产品等项目开发。作为环状RNA平台与肿瘤项目负责人主导的项目获得2022年国家生物药技术创新中心核酸药物“揭榜挂帅”创新项目,为唯一入围的环状RNA项目。已参与申报环状RNA相关专利20项,公开相关学术论文4篇,其中一篇论文正式发表于Molecular Therapy-Nucleic Acids。同时主导并成功开发全套mRNA核心蛋白原料,并建立适用于环状RNA生产的原料酶/配方体系。
  • Head of QualityMingyang Gu
    Mingyang Gu
    AcroImmune Head of Quality
  • President and CEO, Founder, Sirnaomics, Inc.Patrick Lu
    Patrick Lu
    Sirnaomics, Inc. President and CEO, Founder, Sirnaomics, Inc.
  • CEO, Polymed BiotechJason Xiang
    Jason Xiang
    CEO, Polymed Biotech
  • Founder, Asclepius TechnolgoyHuashun Li
    Huashun Li
    Founder, Asclepius Technolgoy
  • Director of Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang UniversityWenbin Qian
    Wenbin Qian
    Director of Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University
  • VP, PersonGen BioTherapeuticsMin Wang
    Min Wang
    VP, PersonGen BioTherapeutics
  • CEO & President Shanghai LIDE Biotech 立迪生物Dr.Danyi Wen
    Dr.Danyi Wen
    CEO & President Shanghai LIDE Biotech 立迪生物
  • Partnership
    The 5th International Cell & Gene Therapy China Summit & Exhibition
    No content
    Exhibition Package
    Exhibition TypePrice

    Note

    6㎡ Standard BoothUSD 5,500

    3m*2m

    9㎡ Standard BoothUSD 7,5003m*3m
    Special Booth (18㎡/ 36㎡/ 72㎡)USD 700/ ㎡Minimum Raw Space: 18㎡


    ◆ Standard booth fee: including exhibition venue, 2.5m high wall panel, plaque production, 6 square meters carpet, negotiation table, two chairs, 10A/220V single-phase socket, two spotlights

    ◆ Empty venues do not carry any display racks and facilities. Exhibitors arrange their own special renovation work or are commissioned by the organization

    Contact Us
    Email:

    rickyli@chujietech.com

    Phone:

    +86-17612157947

    Address:

    NO. 375, ZHONGREN RD. JIADING DISTRICT, SHANGHAI, CHINA PRC